US20160125161A1 - Systems and methods for simulation of hemodialysis access and optimization - Google Patents
Systems and methods for simulation of hemodialysis access and optimization Download PDFInfo
- Publication number
- US20160125161A1 US20160125161A1 US14/595,503 US201514595503A US2016125161A1 US 20160125161 A1 US20160125161 A1 US 20160125161A1 US 201514595503 A US201514595503 A US 201514595503A US 2016125161 A1 US2016125161 A1 US 2016125161A1
- Authority
- US
- United States
- Prior art keywords
- treatment
- post
- geometry
- anatomic model
- received
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 56
- 238000001631 haemodialysis Methods 0.000 title claims abstract description 35
- 230000000322 hemodialysis Effects 0.000 title claims abstract description 35
- 238000005457 optimization Methods 0.000 title description 16
- 238000004088 simulation Methods 0.000 title description 11
- 238000011282 treatment Methods 0.000 claims abstract description 81
- 230000000004 hemodynamic effect Effects 0.000 claims abstract description 74
- 230000002792 vascular Effects 0.000 claims abstract description 36
- 238000002203 pretreatment Methods 0.000 claims abstract description 25
- 210000005166 vasculature Anatomy 0.000 claims abstract description 11
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 230000000747 cardiac effect Effects 0.000 claims description 19
- 230000036772 blood pressure Effects 0.000 claims description 12
- 238000005094 computer simulation Methods 0.000 claims description 11
- 238000013500 data storage Methods 0.000 claims description 2
- 230000006870 function Effects 0.000 description 28
- 230000017531 blood circulation Effects 0.000 description 21
- 210000003462 vein Anatomy 0.000 description 21
- 210000001367 artery Anatomy 0.000 description 15
- 238000010586 diagram Methods 0.000 description 10
- 208000007536 Thrombosis Diseases 0.000 description 8
- 230000003872 anastomosis Effects 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 206010016717 Fistula Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000003484 anatomy Anatomy 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 210000002302 brachial artery Anatomy 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 230000003890 fistula Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 238000011369 optimal treatment Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 241001631457 Cannula Species 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000003881 arterial anastomosis Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002321 radial artery Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- 101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 210000003270 subclavian artery Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003878 venous anastomosis Effects 0.000 description 1
Images
Classifications
-
- G06F19/3437—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3653—Interfaces between patient blood circulation and extra-corporal blood circuit
- A61M1/3655—Arterio-venous shunts or fistulae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
- A61B34/10—Computer-aided planning, simulation or modelling of surgical operations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3653—Interfaces between patient blood circulation and extra-corporal blood circuit
- A61M1/3659—Cannulae pertaining to extracorporeal circulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3653—Interfaces between patient blood circulation and extra-corporal blood circuit
- A61M1/3659—Cannulae pertaining to extracorporeal circulation
- A61M1/3661—Cannulae pertaining to extracorporeal circulation for haemodialysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
- A61B34/10—Computer-aided planning, simulation or modelling of surgical operations
- A61B2034/101—Computer-aided simulation of surgical operations
- A61B2034/102—Modelling of surgical devices, implants or prosthesis
- A61B2034/104—Modelling the effect of the tool, e.g. the effect of an implanted prosthesis or for predicting the effect of ablation or burring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
- A61B34/10—Computer-aided planning, simulation or modelling of surgical operations
- A61B2034/101—Computer-aided simulation of surgical operations
- A61B2034/105—Modelling of the patient, e.g. for ligaments or bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3653—Interfaces between patient blood circulation and extra-corporal blood circuit
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Definitions
- Various embodiments of the present disclosure relate generally to disease assessment, treatment planning, and related methods. More specifically, particular embodiments of the present disclosure relate to systems and methods for simulating and optimizing hemodialysis access.
- Hemodialysis is a process in which an external machine is used to filter blood to remove excess salt and harmful wastes.
- blood may be sent to a hemodialysis machine and back to the patient's circulation.
- the blood may enter and exit a body via a vascular access.
- a vascular access for the blood may be created by introducing cannulas into a patient's vein.
- Blood may then be sent to a hemodialysis machine and back to the patient's circulation via the cannulas.
- a larger vein may be used. This may be possible by shunting arterial blood flow through veins.
- AVF arteriovenous fistula
- AVG arteriovenous graft
- Demand for cardiac output may change from before and after treatment (e.g., pre- and post-shunting of blood flow).
- the arteriovenous connection may increase blood pressure and blood flow in the veins.
- the veins may slowly adapt to this shunting by enlarging in diameter and increasing in thickness. This adaptation process might take anywhere from one month to a year. Once adapted, many different candidate sites may be available for repeated cannulation and hemodialysis.
- the change in cardiac workload for the heart post-treatment may create a health risk. For instance, shunting the blood flow from an artery to a vein may reduce overall system resistance, thus changing hemodynamics in a way that increases cardiac output. This increased demand for cardiac output may result in a larger workload for the heart, and may be linked to an increased risk of congestive heart failure. Further, treatment may change vessel geometry, thus altering regions in vessels that may be prone to thrombosis. An optimal AVG may minimize regions of disturbed hemodynamics and, consequently, minimize regions prone to thrombosis.
- the present disclosure is directed to improving treatment planning by predicting changes in hemodynamics that may result from vascular access procedures.
- systems and methods are disclosed for simulating and optimizing hemodialysis access.
- One method includes: receiving a patient-specific anatomic model of a patient's vasculature; computing a pre-treatment hemodynamic characteristic of a pre-treatment geometry of a portion of the anatomic model; simulating a post-treatment geometry of a vascular access in the portion of the anatomic model; computing a post-treatment hemodynamic characteristic of the post-treatment geometry of the portion of the anatomic model having the vascular access; and generating a representation of the pre-treatment hemodynamic characteristic or the post-treatment hemodynamic characteristic.
- a system for simulating or optimizing hemodialysis access a data storage device storing instructions for simulating or optimizing hemodialysis access; and a processor configured for: receiving a patient-specific anatomic model of a patient's vasculature; computing a pre-treatment hemodynamic characteristic of a pre-treatment geometry of a portion of the anatomic model; simulating a post-treatment geometry of a vascular access in the portion of the anatomic model; computing a post-treatment hemodynamic characteristic of the post-treatment geometry of the portion of the anatomic model having the vascular access; and generating a representation of the pre-treatment hemodynamic characteristic or the post-treatment hemodynamic characteristic.
- a non-transitory computer readable medium for use on a computer system containing computer-executable programming instructions for performing a method of simulating or optimizing hemodialysis access, the method comprising: receiving a patient-specific anatomic model of a patient's vasculature; computing a pre-treatment hemodynamic characteristic of a pre-treatment geometry of a portion of the anatomic model; simulating a post-treatment geometry of a vascular access in the portion of the anatomic model; computing a post-treatment hemodynamic characteristic of the post-treatment geometry of the portion of the anatomic model having the vascular access; and generating a representation of the pre-treatment hemodynamic characteristic or the post-treatment hemodynamic characteristic.
- FIG. 1 is a block diagram of an exemplary system and network for simulating or optimizing hemodialysis access, according to an exemplary embodiment of the present disclosure.
- FIG. 2A is a block diagram of an exemplary method of simulating hemodialysis access, according to an exemplary embodiment of the present disclosure.
- FIG. 2B is a block diagram of an exemplary method of optimizing hemodialysis access, according to an exemplary embodiment of the present disclosure.
- FIG. 3A is a block diagram of an exemplary method of performing predictive modeling and simulation of an AVG, a specific embodiment of simulating hemodialysis access according to an exemplary embodiment of the present disclosure.
- FIG. 3B is a block diagram of an exemplary method of optimizing an AVG, according to an exemplary embodiment of the present disclosure.
- AVGs or AVFs may reduce overall systemic resistance, thus causing increased cardiac output.
- This increased demand for cardiac output may result in a larger workload for the heart, which may be linked to an increased risk of congestive heart failure.
- a goal of vascular access may include increasing blood flow to the veins, while maintaining sufficient perfusion to extremities and ensuring that cardiac demand may not increase to a dangerous level.
- an optimal AVG may minimize regions of disturbed hemodynamics so that regions prone to thrombosis may be minimized as well.
- the present disclosure includes systems and methods for simulating and optimizing hemodialysis access in order to better provide vascular access that improves blood flow but does not endanger the patient.
- the simulations and optimizations include evaluating or comparing various location(s) for the vascular access, as well as graft or fistula geometries.
- Each “treatment” may include vascular access at one location, multiple locations, a single graft or fistula, multiple grafts or fistulas, or a combination thereof.
- One embodiment may include evaluating various treatments, e.g., by simulating and comparing pre- or post-treatment blood flow for different treatments.
- One embodiment may further include performing optimization for the hemodialysis access.
- the optimization may include defining a cost function for determining an optimal hemodialysis characteristic (e.g., blood flow).
- the cost function may incorporate pre- and post-treatment calculations from the simulations of blood flow for different treatments.
- selecting or finding an optimal hemodialysis access treatment may include performing optimization over all possible vascular grafts (e.g., including graft types and/or graft locations in the patient vasculature) to minimize the cost function.
- the optimization may be performed for a subset of available vascular access grafts to minimize a cost function.
- the increase in cardiac demand due to an AVG or an AVF may be modeled by performing a pre-dialysis blood-flow simulation with the original geometry, e.g., by solving 3D Navier-Stokes equations, reduced order models, or using machine learning methods.
- Resistance boundary condition(s) relating blood pressure to flow rate may be provided at the model boundaries.
- cardiac flow and pressure may be coupled to the systemic circulation using a ventricular elastance function.
- the ventricular elastance function may reflect the relationship between cardiac flow, pressure, and systemic circulation since pressure may be based on ventricular volume which, in turn, may be related to a flow-rate using an elastance function.
- Hemodynamics post-treatment may be computed by solving the same equations using a modified geometry reflecting the procedure based on geometric variables that determine the AVG or the AVF.
- the resulting aortic pressure and flow rate, as well as the area enclosed in the left ventricle PV loop, may be used to estimate the changes in cardiac workload, post-treatment.
- the post-treatment cardiac demand and other hemodynamic quantities of interest may be reported to a user (e.g., a physician).
- Hemodynamic quantities of interest may include blood flow, e.g., volume of blood or velocity of blood through a patient's vasculature or portion of a patient's vasculature.
- Other hemodynamic characteristics that may be quantities of interest may include shear stress and/or particle residence time through an AVG. Shear stress and particle residence time through a particular AVG may be observed to provide sufficient blood flow to allow successful dialysis, while reducing the risk of thrombosis in the AVG over time when it is not being used for dialysis.
- Yet another example of hemodynamic characteristics may include distal perfusion pressure and flow in arteries past a fistula. For example, evaluating distal perfusion and flow in vessel locations past an AVF may help to identify whether a graft may “steal” blood from the extremity causing ischemia/symptoms or gangrene in fingers.
- Such methods may help in treatment planning and predicting changes in hemodynamics that result from vascular access procedures.
- FIG. 1 depicts a block diagram of an exemplary system 100 and network for simulating or optimizing hemodialysis access, according to an exemplary embodiment.
- FIG. 1 depicts a plurality of physicians 102 and third party providers 104 , any of whom may be connected to an electronic network 101 , such as the Internet, through one or more computers, servers, and/or handheld mobile devices.
- Physicians 102 and/or third party providers 104 may create or otherwise obtain images of one or more patients' anatomy.
- the physicians 102 and/or third party providers 104 may also obtain any combination of patient-specific information, such as age, medical history, blood pressure, blood viscosity, patient activity or exercise level, etc.
- Physicians 102 and/or third party providers 104 may transmit the anatomical images and/or patient-specific information to server systems 106 over the electronic network 101 .
- Server systems 106 may include storage devices for storing images and data received from physicians 102 and/or third party providers 104 .
- Server systems 106 may also include processing devices for processing images and data stored in the storage devices.
- “patient” may refer to any individual of interest.
- FIGS. 2A and 2B depict flowcharts of a general embodiment for simulating hemodialysis access and optimizing hemodialysis access, respectively.
- FIG. 3A depicts a flowchart of a specific embodiment for simulating hemodialysis access.
- FIG. 3B depicts a flowchart of a specific embodiment for optimizing hemodialysis access.
- FIG. 2A is a block diagram of an exemplary method 200 of simulating hemodialysis access, according to an exemplary embodiment.
- the method of FIG. 2A may be performed by server systems 106 , based on information, images, and data received from physicians 102 and/or third party providers 104 over electronic network 101 .
- step 201 may include acquiring a digital representation of a system of interest (e.g., of an individual's anatomy) and reconstructing a computational model (e.g., representing the functioning of the system of interest).
- the digital representation may include an artery and a vein that may be anastomosed or shunted, as well as all vessels branching off the arteriovenous system encompassing arteries and veins of a system of interest.
- the vessels may be traced back to the aorta.
- a three dimensional model of the arteries may be reconstructed, e.g., by computing centerlines through the model and segmenting the arteries and veins across centerlines.
- step 201 may further include acquiring candidate parameters for anastomoses (e.g., location of an anastomosis).
- Step 201 may also include acquiring infeasible surgeries or any extraneous constraints that may make certain surgical configurations infeasible.
- step 203 may include computing hemodynamics of a pre-treatment AV system geometry.
- Blood flow characteristics in the reconstructed geometry may be computed by solving the Navier-Stokes equations.
- the computation may include constructing a finite element mesh over the reconstructed geometry (e.g., from step 201 ) and specifying appropriate boundary conditions that relate blood pressure to flow rate at outlet surfaces.
- the boundary conditions may be calculated based on local tissue perfusion demand. Other boundary conditions, including capacitance of micro-vessels, may also be provided.
- a time-varying elastance function of the left ventricle may be given as input. Otherwise, blood pressure or velocity may be provided as input at inlet surfaces.
- step 203 may include using a reduced order model to solve for the hemodynamics and related quantities of interest.
- the reduced order model may involve combining the Poiseulle's law with non-linear stenosis pressure loss models, as well as Bernoulli's equation to account for kinetic energy of blood.
- step 203 may involve solving the one dimensional wave equation.
- step 203 may include using a machine learning approach to solve for the hemodynamics (e.g., as described in U.S. Nonprovisional application Ser. No. 13/895,893 filed May 16, 2013, the entire disclosure of which is hereby incorporated by reference in its entirety).
- Features of the computational model that affect hemodynamics may be calculated.
- a regressor computed using a database of 3D simulations may be used to map the inputs to hemodynamic quantities of interest (e.g., as described in the application).
- step 205 may include simulating and computing hemodynamics for a post-treatment anatomy geometry.
- Post-treatment patient geometry may be created by altering the segmentation at the candidate anastomoses sites to mimic the planned treatment geometry. Any of the three broad classes of methods described in step 203 may be used to calculate hemodynamic quantities of interest post-treatment.
- step 207 may include outputting the results of the simulation. For example, the difference in hemodynamics pre-treatment versus post-treatment may be displayed or reported to a user (e.g., a physician). In one embodiment, step 207 may further include creating a rendering for the comparison, including graphical, pictorial, and/or interactive features.
- FIG. 2B is a block diagram of an exemplary method 220 of optimizing hemodialysis access, according to an exemplary embodiment.
- the method of FIG. 2B may be performed by server systems 106 , based on information, images, and data received from physicians 102 and/or third party providers 104 over electronic network 101 .
- Simulations may offer a viable alternative to calculating optimal treatment geometry, including one or more AVGs and/or AVFs at one or more locations.
- Optimal parameters may be computed by minimizing a cost function.
- step 221 may include defining, receiving, or identifying a cost function for optimizing hemodialysis access.
- a general cost function may be defined as:
- C output may be a function of the cardiac output of the heart
- C flow may be a function of blood flow through the veins and flow through arteries distal to shunt location
- C hemo may be a function of risk of clot formation near shunt location
- C other may be a function of any other problem-specific cost function that may depend on the hemodynamics. More specifically, the cost function may be defined as:
- ⁇ 1 , ⁇ 2 , ⁇ 3 , and ⁇ 4 may include weights for different cost functions.
- ⁇ 1 , ⁇ 2 , ⁇ 3 , and ⁇ 4 may have different units and a user may choose to pick values based on patient-history (e.g., for a patient who has had previous coronary artery bypass graft surgery, ⁇ 2 , ⁇ 3 and ⁇ i may be taken to be zero so that only the first term may be used in the optimization).
- E in the first term may include the difference between cardiac outputs (E post ⁇ E pre ), which may be defined as:
- H may be an area of low wall shear stresses defined as:
- ⁇ may be the local WSS and ⁇ c may be the critical cutoff, below which surfaces may be deemed disturbed.
- the cost function may include a term (e.g., “T”) that indicates a propensity for thrombosis, e.g., by modeling blood rheology or clotting.
- Various coagulation models T based on hemodynamics and blood viscosity may be used to account for one or more characteristics of blood that may promote or inhibit intravascular coagulation, for instance: blood composition, factors that influence activation or inhibition of platelets, factors that influence activation or inhibition of a clotting cascade (e.g., at any point in a multilayered cascade), anti-coagulant presence or usage versus no anti-coagulation presence or usage, viscosity of blood (since dialysis patients may be anemic), etc.
- Factors that influence activation or inhibition of platelets may include, for example, initiation of platelet aggregation inhibition.
- the coagulation models may further account for shear rate and/or chemical pathways, for instance, in modeling the blood flow of a patient using anticoagulants.
- T may be calculated by advecting particles using the blood velocity field calculated from the hemodynamics.
- particles may be defined based on a platelet activation function, which, in turn, may be defined based on a velocity gradient (e.g., with a deformation tensor). For instance, an active platelet may be identified when an activation threshold is crossed. Calculating T may then involve tracing the evolution or activity of the active platelet over time.
- Another exemplary platelet activation model may include a power law model based on shear stresses, in which advecting particles may involve releasing simulated blood cells at the inlet of a problem geometry and propagating the cells based on the blood velocity field to trace the path of the simulated blood cells over a period of time.
- a power law model may be used to calculate the residence time of the blood cells, which quantifies the propensity of the blood cells to form clots. For instance, the higher the residence time, the higher the propensity for thrombus formation.
- a patient's blood viscosity may affect the velocity field and, consequently, the residence time.
- step 223 may include selecting or identifying an optimization method to find the parameters that minimize the cost function C.
- Any optimization method including (i) derivative-free optimization techniques (e.g., pattern search, Nelder-Mead algorithm, etc.), (ii) gradient-based quasi-Newtonian algorithm (e.g., BFGS), or (iii) global optimization methods (e.g., evolutionary search algorithm) may be used to find the optima. Constraints may be incorporated by mapping parameters in the constraint region to a very high value (e.g., 10 ⁇ 10).
- Step 225 may include performing the optimization method
- step 227 may include outputting the results of the optimization method and/or updating or changing the cost function to solve for a different optima.
- FIG. 3A is a block diagram of an exemplary method 300 of performing predictive modeling and simulation of an AVG between the brachial artery and antecubital vein, which is one exemplary embodiment of simulating hemodialysis access.
- FIG. 3B is a block diagram of an exemplary method 320 of optimizing an AVG, according to an exemplary embodiment.
- the methods of FIGS. 3A and 3B may be performed by server systems 106 , based on information, images, and data received from physicians 102 and/or third party providers 104 over electronic network 101 .
- Exemplary methods 300 and 320 may apply to an AVG between any other artery and vein as well.
- exemplary methods 300 and 320 may be extended to an AVF where graft-specific parameters, e.g., radius, may be removed from the optimization parameter set.
- step 301 may include acquiring a digital representation of a system (e.g., a patient's vasculature or anatomy of interest) and reconstructing a computational model to represent a hemodynamic characteristic of the system.
- the system and computational model may include a portion of a patient's aorta, brachial artery, antecubital vein, and (if available) other arteries, e.g., cephalic, subclavian, and radial artery.
- a three dimensional model of the brachial artery and antecubital vein, part of the aorta, and other visible arteries and veins may be reconstructed using a combination of automated algorithms and manual editing.
- Step 301 may further include receiving or measuring available graft radii.
- Candidate sites or parameters for anastomoses in the artery and veins may also be measured or received as input, and infeasible surgical geometries may be used as constraints.
- step 303 may include computing hemodynamics in the model pre-AVG implantation.
- Blood flow simulations in the reconstructed geometry (e.g., from step 301 ) may be performed by constructing a finite element mesh of the computational model. Blood pressure and velocities may be calculated at the vertices of the finite element mesh, e.g., by solving the Navier-Stokes equations.
- the aortic inlet flow and blood pressure may be coupled to a reduced-order heart model driven by a ventricular elastance function.
- resistance boundary conditions which relate blood pressure to flow-rate may be prescribed. These values may be obtained for different arteries by determining the ratio of population-averaged nominal pressure to nominal flow-rate. For instance, pressure and flow-rate for the radial artery may be ⁇ 150 mm Hg and ⁇ 600 ml/min, respectively. Hemodynamic quantities of interest may be calculated from blood pressure and velocity found using the Navier-Stokes equations.
- step 305 may include modeling a virtual AVG.
- step 305 may include constructing a virtual model of the AVG by inserting a graft at candidate sites (e.g., sites provided in step 301 ). This may be performed by creating a cylindrical vessel of the radius (e.g., from step 301 ) and creating an anastomosis using the cylindrical vessel and a series of Boolean operations on the computational geometry constructed from step 301 .
- an implicit model of a cylindrical graft may be used to model the geometric changes associated with inserting a graft. In one embodiment, this procedure may be performed twice, once at the brachial artery and once at the antecubital vein. A finite element mesh of the new geometry may be constructed.
- step 307 may include calculating hemodynamic quantities of interest post-implantation of an AVG.
- step 309 may include reporting a comparison of the pre-AVG hemodynamic quantities of interest to modeled post-AVG hemodynamic quantities of interest. For example, step 309 may include reporting the comparison for one or more of the candidate AVG parameters that were provided as input in step 301 .
- method 320 shown in FIG. 3B may include optimizing the radius and location of an AVG.
- step 321 of method 320 may include defining a cost function for optimizing AVG implantation.
- the cost function may include parameters that contribute to AVG optimization.
- one parameter may include graft radius. Graft radius may affect shunting resistance of the AVG. A higher graft radius may result in larger blood flow being shunted through the AVG. Length, as well as curvature of vascular graft, may also be treated as a parameter. The curvature of the graft may be important since the graft may go down the forearm, take a 180° turn, and return to the antecubital space.
- the angle of the AVG may impact the local hemodynamics and may result in adverse hemodynamics, e.g., flow stasis, recirculation, etc.
- Location of anastomosis may be another parameter which impacts the outcome of treatment.
- the graft may take various different pathways, e.g., depending on the location of the arterial and venous anastomosis.
- a desired output of the model may include a choice of an optimal site for anastomosis.
- An exemplary cost function may be defined as
- the first, second, and last terms of the above equation may be the same as defined in the general embodiment (and normalized by their nominal value).
- An AVG-specific term e.g., Q distal
- Q distal may be added to ensure that most of the flow is not shunted and that enough blood flow goes to the extremities. This may help prevent a condition where a patient loses sensation or has compromised circulation in extremities soon after the surgery.
- Q distal may be the blood flow distal to the arterial anastomosis site.
- step 323 may include receiving, creating, or identifying a termination criterion.
- step 325 may include using a derivative-free Nelder-Mead optimization method to compute parameters that may minimize the cost function. A random initial parameter set may be chosen. Subsequently, at each step in the Nelder-Mead algorithm, a new parameter may be identified by constructing simplexes using existing points and choosing an operation between reflection, reduction, contraction or reduction.
- step 327 may include determining whether the computed parameters from step 325 meet a termination criterion and performing step 325 successively until the termination criterion is reached.
- step 329 may include outputting the parameters computed where the termination criterion was met, as optimal therapy parameters, e.g., to an electronic storage medium and/or to a user interface.
- Hemodialysis may present its own set of risks, including cardiovascular risks stemming from dialysis access.
- Various access treatments may change vessel geometry, altering hemodynamics and causing thrombosis or dangerous levels of cardiac demand.
- the present disclosure thus provides systems and methods to improve treatment planning by predicting changes in hemodynamics that may result from vascular access procedures.
- the systems and methods include simulating access treatments and comparing results from the simulations to provide optimal treatments for a patient.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Robotics (AREA)
- Molecular Biology (AREA)
- External Artificial Organs (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Abstract
Description
- This application claims priority to U.S. Provisional Application No. 62/074,698 filed Nov. 4, 2014, the entire disclosure of which is hereby incorporated herein by reference in its entirety.
- Various embodiments of the present disclosure relate generally to disease assessment, treatment planning, and related methods. More specifically, particular embodiments of the present disclosure relate to systems and methods for simulating and optimizing hemodialysis access.
- Hemodialysis is a process in which an external machine is used to filter blood to remove excess salt and harmful wastes. For example, blood may be sent to a hemodialysis machine and back to the patient's circulation. The blood may enter and exit a body via a vascular access. For instance, a vascular access for the blood may be created by introducing cannulas into a patient's vein. Blood may then be sent to a hemodialysis machine and back to the patient's circulation via the cannulas. To enable ease of cannulation and ensure availability of many candidate access sites, a larger vein may be used. This may be possible by shunting arterial blood flow through veins. Two kinds of vascular access procedures include—arteriovenous fistula (AVF) (in which an artery and a vein may be directly connected) and arteriovenous graft (AVG) (in which a synthetic graft may be attached between an artery and a vein). Demand for cardiac output may change from before and after treatment (e.g., pre- and post-shunting of blood flow). For example, the arteriovenous connection may increase blood pressure and blood flow in the veins. The veins may slowly adapt to this shunting by enlarging in diameter and increasing in thickness. This adaptation process might take anywhere from one month to a year. Once adapted, many different candidate sites may be available for repeated cannulation and hemodialysis.
- However, the change in cardiac workload for the heart post-treatment may create a health risk. For instance, shunting the blood flow from an artery to a vein may reduce overall system resistance, thus changing hemodynamics in a way that increases cardiac output. This increased demand for cardiac output may result in a larger workload for the heart, and may be linked to an increased risk of congestive heart failure. Further, treatment may change vessel geometry, thus altering regions in vessels that may be prone to thrombosis. An optimal AVG may minimize regions of disturbed hemodynamics and, consequently, minimize regions prone to thrombosis.
- Thus, a desire exists to ensure that there is enough blood flow to allow successful dialysis and maintain sufficient perfusion to extremities, and at the same time, ensure that change to hemodynamics is minimal so that cardiac demand may not increase to a point that endangers a patient. Furthermore, a desire exists to improve treatment planning by optimizing vascular access graft locations and/or vascular access graft types. The present disclosure is directed to improving treatment planning by predicting changes in hemodynamics that may result from vascular access procedures.
- The foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the disclosure.
- According to certain aspects of the present disclosure, systems and methods are disclosed for simulating and optimizing hemodialysis access.
- One method includes: receiving a patient-specific anatomic model of a patient's vasculature; computing a pre-treatment hemodynamic characteristic of a pre-treatment geometry of a portion of the anatomic model; simulating a post-treatment geometry of a vascular access in the portion of the anatomic model; computing a post-treatment hemodynamic characteristic of the post-treatment geometry of the portion of the anatomic model having the vascular access; and generating a representation of the pre-treatment hemodynamic characteristic or the post-treatment hemodynamic characteristic.
- In accordance with another embodiment, a system for simulating or optimizing hemodialysis access: a data storage device storing instructions for simulating or optimizing hemodialysis access; and a processor configured for: receiving a patient-specific anatomic model of a patient's vasculature; computing a pre-treatment hemodynamic characteristic of a pre-treatment geometry of a portion of the anatomic model; simulating a post-treatment geometry of a vascular access in the portion of the anatomic model; computing a post-treatment hemodynamic characteristic of the post-treatment geometry of the portion of the anatomic model having the vascular access; and generating a representation of the pre-treatment hemodynamic characteristic or the post-treatment hemodynamic characteristic.
- In accordance with another embodiment, a non-transitory computer readable medium for use on a computer system containing computer-executable programming instructions for performing a method of simulating or optimizing hemodialysis access, the method comprising: receiving a patient-specific anatomic model of a patient's vasculature; computing a pre-treatment hemodynamic characteristic of a pre-treatment geometry of a portion of the anatomic model; simulating a post-treatment geometry of a vascular access in the portion of the anatomic model; computing a post-treatment hemodynamic characteristic of the post-treatment geometry of the portion of the anatomic model having the vascular access; and generating a representation of the pre-treatment hemodynamic characteristic or the post-treatment hemodynamic characteristic.
- Additional objects and advantages of the disclosed embodiments will be set forth in part in the description that follows, and in part will be apparent from the description, or may be learned by practice of the disclosed embodiments. The objects and advantages of the disclosed embodiments will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
- It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the disclosed embodiments, as claimed.
- The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate various exemplary embodiments and together with the description, serve to explain the principles of the disclosed embodiments.
-
FIG. 1 is a block diagram of an exemplary system and network for simulating or optimizing hemodialysis access, according to an exemplary embodiment of the present disclosure. -
FIG. 2A is a block diagram of an exemplary method of simulating hemodialysis access, according to an exemplary embodiment of the present disclosure. -
FIG. 2B is a block diagram of an exemplary method of optimizing hemodialysis access, according to an exemplary embodiment of the present disclosure. -
FIG. 3A is a block diagram of an exemplary method of performing predictive modeling and simulation of an AVG, a specific embodiment of simulating hemodialysis access according to an exemplary embodiment of the present disclosure. -
FIG. 3B is a block diagram of an exemplary method of optimizing an AVG, according to an exemplary embodiment of the present disclosure. - Reference will now be made in detail to the exemplary embodiments of the disclosure, examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts.
- Shunting of blood flow from an artery to a vein via AVGs or AVFs may reduce overall systemic resistance, thus causing increased cardiac output. This increased demand for cardiac output may result in a larger workload for the heart, which may be linked to an increased risk of congestive heart failure. Thus, a goal of vascular access may include increasing blood flow to the veins, while maintaining sufficient perfusion to extremities and ensuring that cardiac demand may not increase to a dangerous level. Further, an optimal AVG may minimize regions of disturbed hemodynamics so that regions prone to thrombosis may be minimized as well.
- The present disclosure includes systems and methods for simulating and optimizing hemodialysis access in order to better provide vascular access that improves blood flow but does not endanger the patient. For example, the simulations and optimizations include evaluating or comparing various location(s) for the vascular access, as well as graft or fistula geometries. Each “treatment” may include vascular access at one location, multiple locations, a single graft or fistula, multiple grafts or fistulas, or a combination thereof. One embodiment may include evaluating various treatments, e.g., by simulating and comparing pre- or post-treatment blood flow for different treatments.
- One embodiment may further include performing optimization for the hemodialysis access. For example, the optimization may include defining a cost function for determining an optimal hemodialysis characteristic (e.g., blood flow). The cost function may incorporate pre- and post-treatment calculations from the simulations of blood flow for different treatments. In one case, selecting or finding an optimal hemodialysis access treatment may include performing optimization over all possible vascular grafts (e.g., including graft types and/or graft locations in the patient vasculature) to minimize the cost function. In another case, the optimization may be performed for a subset of available vascular access grafts to minimize a cost function.
- For example, the increase in cardiac demand due to an AVG or an AVF may be modeled by performing a pre-dialysis blood-flow simulation with the original geometry, e.g., by solving 3D Navier-Stokes equations, reduced order models, or using machine learning methods. Resistance boundary condition(s) relating blood pressure to flow rate may be provided at the model boundaries. At the aortic inlet surface, cardiac flow and pressure may be coupled to the systemic circulation using a ventricular elastance function. The ventricular elastance function may reflect the relationship between cardiac flow, pressure, and systemic circulation since pressure may be based on ventricular volume which, in turn, may be related to a flow-rate using an elastance function.
- Hemodynamics post-treatment may be computed by solving the same equations using a modified geometry reflecting the procedure based on geometric variables that determine the AVG or the AVF. The resulting aortic pressure and flow rate, as well as the area enclosed in the left ventricle PV loop, may be used to estimate the changes in cardiac workload, post-treatment. The post-treatment cardiac demand and other hemodynamic quantities of interest may be reported to a user (e.g., a physician).
- Hemodynamic quantities of interest may include blood flow, e.g., volume of blood or velocity of blood through a patient's vasculature or portion of a patient's vasculature. Other hemodynamic characteristics that may be quantities of interest may include shear stress and/or particle residence time through an AVG. Shear stress and particle residence time through a particular AVG may be observed to provide sufficient blood flow to allow successful dialysis, while reducing the risk of thrombosis in the AVG over time when it is not being used for dialysis. Yet another example of hemodynamic characteristics may include distal perfusion pressure and flow in arteries past a fistula. For example, evaluating distal perfusion and flow in vessel locations past an AVF may help to identify whether a graft may “steal” blood from the extremity causing ischemia/symptoms or gangrene in fingers.
- Such methods may help in treatment planning and predicting changes in hemodynamics that result from vascular access procedures.
- Referring now to the figures,
FIG. 1 depicts a block diagram of anexemplary system 100 and network for simulating or optimizing hemodialysis access, according to an exemplary embodiment. Specifically,FIG. 1 depicts a plurality ofphysicians 102 andthird party providers 104, any of whom may be connected to an electronic network 101, such as the Internet, through one or more computers, servers, and/or handheld mobile devices.Physicians 102 and/orthird party providers 104 may create or otherwise obtain images of one or more patients' anatomy. Thephysicians 102 and/orthird party providers 104 may also obtain any combination of patient-specific information, such as age, medical history, blood pressure, blood viscosity, patient activity or exercise level, etc.Physicians 102 and/orthird party providers 104 may transmit the anatomical images and/or patient-specific information toserver systems 106 over the electronic network 101.Server systems 106 may include storage devices for storing images and data received fromphysicians 102 and/orthird party providers 104.Server systems 106 may also include processing devices for processing images and data stored in the storage devices. For the present disclosure, “patient” may refer to any individual of interest. -
FIGS. 2A and 2B depict flowcharts of a general embodiment for simulating hemodialysis access and optimizing hemodialysis access, respectively.FIG. 3A depicts a flowchart of a specific embodiment for simulating hemodialysis access.FIG. 3B depicts a flowchart of a specific embodiment for optimizing hemodialysis access. -
FIG. 2A is a block diagram of anexemplary method 200 of simulating hemodialysis access, according to an exemplary embodiment. The method ofFIG. 2A may be performed byserver systems 106, based on information, images, and data received fromphysicians 102 and/orthird party providers 104 over electronic network 101. - In one embodiment, step 201 may include acquiring a digital representation of a system of interest (e.g., of an individual's anatomy) and reconstructing a computational model (e.g., representing the functioning of the system of interest). For example, the digital representation may include an artery and a vein that may be anastomosed or shunted, as well as all vessels branching off the arteriovenous system encompassing arteries and veins of a system of interest. In one embodiment, the vessels may be traced back to the aorta. A three dimensional model of the arteries may be reconstructed, e.g., by computing centerlines through the model and segmenting the arteries and veins across centerlines.
- In one embodiment, step 201 may further include acquiring candidate parameters for anastomoses (e.g., location of an anastomosis). Step 201 may also include acquiring infeasible surgeries or any extraneous constraints that may make certain surgical configurations infeasible.
- In one embodiment, step 203 may include computing hemodynamics of a pre-treatment AV system geometry. Blood flow characteristics in the reconstructed geometry may be computed by solving the Navier-Stokes equations. For example, the computation may include constructing a finite element mesh over the reconstructed geometry (e.g., from step 201) and specifying appropriate boundary conditions that relate blood pressure to flow rate at outlet surfaces. The boundary conditions may be calculated based on local tissue perfusion demand. Other boundary conditions, including capacitance of micro-vessels, may also be provided. At the aortic inlet, a time-varying elastance function of the left ventricle may be given as input. Otherwise, blood pressure or velocity may be provided as input at inlet surfaces.
- Alternatively or in addition,
step 203 may include using a reduced order model to solve for the hemodynamics and related quantities of interest. The reduced order model may involve combining the Poiseulle's law with non-linear stenosis pressure loss models, as well as Bernoulli's equation to account for kinetic energy of blood. Alternately or in addition,step 203 may involve solving the one dimensional wave equation. - Alternatively or in addition,
step 203 may include using a machine learning approach to solve for the hemodynamics (e.g., as described in U.S. Nonprovisional application Ser. No. 13/895,893 filed May 16, 2013, the entire disclosure of which is hereby incorporated by reference in its entirety). Features of the computational model that affect hemodynamics may be calculated. In some cases, a regressor computed using a database of 3D simulations may be used to map the inputs to hemodynamic quantities of interest (e.g., as described in the application). - In one embodiment, step 205 may include simulating and computing hemodynamics for a post-treatment anatomy geometry. Post-treatment patient geometry may be created by altering the segmentation at the candidate anastomoses sites to mimic the planned treatment geometry. Any of the three broad classes of methods described in
step 203 may be used to calculate hemodynamic quantities of interest post-treatment. - In one embodiment, step 207 may include outputting the results of the simulation. For example, the difference in hemodynamics pre-treatment versus post-treatment may be displayed or reported to a user (e.g., a physician). In one embodiment, step 207 may further include creating a rendering for the comparison, including graphical, pictorial, and/or interactive features.
-
FIG. 2B is a block diagram of anexemplary method 220 of optimizing hemodialysis access, according to an exemplary embodiment. The method ofFIG. 2B may be performed byserver systems 106, based on information, images, and data received fromphysicians 102 and/orthird party providers 104 over electronic network 101. - Simulations may offer a viable alternative to calculating optimal treatment geometry, including one or more AVGs and/or AVFs at one or more locations. Optimal parameters may be computed by minimizing a cost function. In one embodiment, step 221 may include defining, receiving, or identifying a cost function for optimizing hemodialysis access. For example, a general cost function may be defined as:
-
C=α 1 C output(pre,post)−α2 C flow+α3 C hemo+α4 C clot+α5 C other - Coutput(pre,post) may be a function of the cardiac output of the heart, Cflow may be a function of blood flow through the veins and flow through arteries distal to shunt location, Chemo may be a function of risk of clot formation near shunt location, and Cother may be a function of any other problem-specific cost function that may depend on the hemodynamics. More specifically, the cost function may be defined as:
-
C=α 1(E post −E pre)−α2(Q dialyzer)+α3(H post −H pre)+α4(T post −T pre)+Σi=1 Nβi f i(P,v) - α1, α2, α3, and α4 may include weights for different cost functions. α1, α2, α3, and α4 may have different units and a user may choose to pick values based on patient-history (e.g., for a patient who has had previous coronary artery bypass graft surgery, α2, α3 and βi may be taken to be zero so that only the first term may be used in the optimization). E in the first term may include the difference between cardiac outputs (Epost−Epre), which may be defined as:
-
E=∫PdV - P and V may be defined as pressure and volume of left ventricle. The second term, Qdialyzer may include the flow through the dialyzer intended to be maximized. H in the third term (Hpost−Hpre), may include terms which quantify disturbed hemodynamics. For instance, H may be an area of low wall shear stresses defined as:
-
H=∫I(τ<τc)dA - τ may be the local WSS and τc may be the critical cutoff, below which surfaces may be deemed disturbed.
- Furthermore, thrombosis of a graft may contribute to AVG failure. In one embodiment, the cost function may include a term (e.g., “T”) that indicates a propensity for thrombosis, e.g., by modeling blood rheology or clotting. Various coagulation models T based on hemodynamics and blood viscosity may be used to account for one or more characteristics of blood that may promote or inhibit intravascular coagulation, for instance: blood composition, factors that influence activation or inhibition of platelets, factors that influence activation or inhibition of a clotting cascade (e.g., at any point in a multilayered cascade), anti-coagulant presence or usage versus no anti-coagulation presence or usage, viscosity of blood (since dialysis patients may be anemic), etc. Factors that influence activation or inhibition of platelets may include, for example, initiation of platelet aggregation inhibition. The coagulation models may further account for shear rate and/or chemical pathways, for instance, in modeling the blood flow of a patient using anticoagulants.
- In one embodiment, T may be calculated by advecting particles using the blood velocity field calculated from the hemodynamics. For example, particles may be defined based on a platelet activation function, which, in turn, may be defined based on a velocity gradient (e.g., with a deformation tensor). For instance, an active platelet may be identified when an activation threshold is crossed. Calculating T may then involve tracing the evolution or activity of the active platelet over time. Another exemplary platelet activation model may include a power law model based on shear stresses, in which advecting particles may involve releasing simulated blood cells at the inlet of a problem geometry and propagating the cells based on the blood velocity field to trace the path of the simulated blood cells over a period of time. Such a power law model may be used to calculate the residence time of the blood cells, which quantifies the propensity of the blood cells to form clots. For instance, the higher the residence time, the higher the propensity for thrombus formation. A patient's blood viscosity may affect the velocity field and, consequently, the residence time.
- Any other term encoding hemodynamic quantities of interest that may be added to the cost function, which may be represented by the term Σi=1 Nβifi(P,v). Non-linear combinations of the terms may also be used.
- To find an optimal treatment, one embodiment of
step 223 may include selecting or identifying an optimization method to find the parameters that minimize the cost function C. Any optimization method, including (i) derivative-free optimization techniques (e.g., pattern search, Nelder-Mead algorithm, etc.), (ii) gradient-based quasi-Newtonian algorithm (e.g., BFGS), or (iii) global optimization methods (e.g., evolutionary search algorithm) may be used to find the optima. Constraints may be incorporated by mapping parameters in the constraint region to a very high value (e.g., 10̂10). Step 225 may include performing the optimization method, and step 227 may include outputting the results of the optimization method and/or updating or changing the cost function to solve for a different optima. -
FIG. 3A is a block diagram of anexemplary method 300 of performing predictive modeling and simulation of an AVG between the brachial artery and antecubital vein, which is one exemplary embodiment of simulating hemodialysis access.FIG. 3B is a block diagram of anexemplary method 320 of optimizing an AVG, according to an exemplary embodiment. The methods ofFIGS. 3A and 3B may be performed byserver systems 106, based on information, images, and data received fromphysicians 102 and/orthird party providers 104 over electronic network 101.Exemplary methods exemplary methods - In one embodiment, step 301 may include acquiring a digital representation of a system (e.g., a patient's vasculature or anatomy of interest) and reconstructing a computational model to represent a hemodynamic characteristic of the system. For example, the system and computational model may include a portion of a patient's aorta, brachial artery, antecubital vein, and (if available) other arteries, e.g., cephalic, subclavian, and radial artery. A three dimensional model of the brachial artery and antecubital vein, part of the aorta, and other visible arteries and veins may be reconstructed using a combination of automated algorithms and manual editing.
- Step 301 may further include receiving or measuring available graft radii. Candidate sites or parameters for anastomoses in the artery and veins may also be measured or received as input, and infeasible surgical geometries may be used as constraints.
- In one embodiment, step 303 may include computing hemodynamics in the model pre-AVG implantation. Blood flow simulations in the reconstructed geometry (e.g., from step 301) may be performed by constructing a finite element mesh of the computational model. Blood pressure and velocities may be calculated at the vertices of the finite element mesh, e.g., by solving the Navier-Stokes equations. At the inlet to the model, the aortic inlet flow and blood pressure may be coupled to a reduced-order heart model driven by a ventricular elastance function. At the outlets, resistance boundary conditions which relate blood pressure to flow-rate may be prescribed. These values may be obtained for different arteries by determining the ratio of population-averaged nominal pressure to nominal flow-rate. For instance, pressure and flow-rate for the radial artery may be ˜150 mm Hg and ˜600 ml/min, respectively. Hemodynamic quantities of interest may be calculated from blood pressure and velocity found using the Navier-Stokes equations.
- In one embodiment, step 305 may include modeling a virtual AVG. For example, step 305 may include constructing a virtual model of the AVG by inserting a graft at candidate sites (e.g., sites provided in step 301). This may be performed by creating a cylindrical vessel of the radius (e.g., from step 301) and creating an anastomosis using the cylindrical vessel and a series of Boolean operations on the computational geometry constructed from
step 301. Alternatively, if an implicit representation of the patient-specific geometry is available, an implicit model of a cylindrical graft may be used to model the geometric changes associated with inserting a graft. In one embodiment, this procedure may be performed twice, once at the brachial artery and once at the antecubital vein. A finite element mesh of the new geometry may be constructed. - In one embodiment, step 307 may include calculating hemodynamic quantities of interest post-implantation of an AVG. In one embodiment, step 309 may include reporting a comparison of the pre-AVG hemodynamic quantities of interest to modeled post-AVG hemodynamic quantities of interest. For example, step 309 may include reporting the comparison for one or more of the candidate AVG parameters that were provided as input in
step 301. - Regarding
FIG. 3B ,method 320 shown inFIG. 3B may include optimizing the radius and location of an AVG. In one embodiment, step 321 ofmethod 320 may include defining a cost function for optimizing AVG implantation. The cost function may include parameters that contribute to AVG optimization. For example, one parameter may include graft radius. Graft radius may affect shunting resistance of the AVG. A higher graft radius may result in larger blood flow being shunted through the AVG. Length, as well as curvature of vascular graft, may also be treated as a parameter. The curvature of the graft may be important since the graft may go down the forearm, take a 180° turn, and return to the antecubital space. Further, the angle of the AVG may impact the local hemodynamics and may result in adverse hemodynamics, e.g., flow stasis, recirculation, etc. Location of anastomosis may be another parameter which impacts the outcome of treatment. The graft may take various different pathways, e.g., depending on the location of the arterial and venous anastomosis. A desired output of the model may include a choice of an optimal site for anastomosis. An exemplary cost function may be defined as -
- The first, second, and last terms of the above equation may be the same as defined in the general embodiment (and normalized by their nominal value). An AVG-specific term (e.g., Qdistal) may be added to ensure that most of the flow is not shunted and that enough blood flow goes to the extremities. This may help prevent a condition where a patient loses sensation or has compromised circulation in extremities soon after the surgery. Specifically, Qdistal may be the blood flow distal to the arterial anastomosis site.
- In one embodiment, step 323 may include receiving, creating, or identifying a termination criterion. In one embodiment, step 325 may include using a derivative-free Nelder-Mead optimization method to compute parameters that may minimize the cost function. A random initial parameter set may be chosen. Subsequently, at each step in the Nelder-Mead algorithm, a new parameter may be identified by constructing simplexes using existing points and choosing an operation between reflection, reduction, contraction or reduction. In one embodiment, step 327 may include determining whether the computed parameters from
step 325 meet a termination criterion and performingstep 325 successively until the termination criterion is reached. In one embodiment, step 329 may include outputting the parameters computed where the termination criterion was met, as optimal therapy parameters, e.g., to an electronic storage medium and/or to a user interface. - Hemodialysis may present its own set of risks, including cardiovascular risks stemming from dialysis access. Various access treatments may change vessel geometry, altering hemodynamics and causing thrombosis or dangerous levels of cardiac demand. A desire exists to ensure that there is enough blood flow to allow successful dialysis while also ensuring that change to hemodynamics does not endanger a patient. The present disclosure thus provides systems and methods to improve treatment planning by predicting changes in hemodynamics that may result from vascular access procedures. The systems and methods include simulating access treatments and comparing results from the simulations to provide optimal treatments for a patient.
- Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
Claims (20)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/595,503 US9336354B1 (en) | 2014-11-04 | 2015-01-13 | Systems and methods for simulation of hemodialysis access and optimization |
JP2017523809A JP6637975B2 (en) | 2014-11-04 | 2015-10-28 | System and method for simulation and optimization of hemodialysis access |
EP15794404.2A EP3215967B1 (en) | 2014-11-04 | 2015-10-28 | Systems and methods for simulation of hemodialsis access and optimization |
PCT/US2015/057731 WO2016073246A1 (en) | 2014-11-04 | 2015-10-28 | Systems and methods for simulation of hemodialsis access and optimization |
US15/054,622 US10314654B2 (en) | 2014-11-04 | 2016-02-26 | Systems and methods for simulation of hemodialysis access and optimization |
US16/397,218 US20190247124A1 (en) | 2014-11-04 | 2019-04-29 | Systems and methods for simulation of hemodialysis access and optimization |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462074698P | 2014-11-04 | 2014-11-04 | |
US14/595,503 US9336354B1 (en) | 2014-11-04 | 2015-01-13 | Systems and methods for simulation of hemodialysis access and optimization |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/054,622 Continuation US10314654B2 (en) | 2014-11-04 | 2016-02-26 | Systems and methods for simulation of hemodialysis access and optimization |
Publications (2)
Publication Number | Publication Date |
---|---|
US20160125161A1 true US20160125161A1 (en) | 2016-05-05 |
US9336354B1 US9336354B1 (en) | 2016-05-10 |
Family
ID=55852965
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/595,503 Active US9336354B1 (en) | 2014-11-04 | 2015-01-13 | Systems and methods for simulation of hemodialysis access and optimization |
US15/054,622 Active US10314654B2 (en) | 2014-11-04 | 2016-02-26 | Systems and methods for simulation of hemodialysis access and optimization |
US16/397,218 Pending US20190247124A1 (en) | 2014-11-04 | 2019-04-29 | Systems and methods for simulation of hemodialysis access and optimization |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/054,622 Active US10314654B2 (en) | 2014-11-04 | 2016-02-26 | Systems and methods for simulation of hemodialysis access and optimization |
US16/397,218 Pending US20190247124A1 (en) | 2014-11-04 | 2019-04-29 | Systems and methods for simulation of hemodialysis access and optimization |
Country Status (4)
Country | Link |
---|---|
US (3) | US9336354B1 (en) |
EP (1) | EP3215967B1 (en) |
JP (1) | JP6637975B2 (en) |
WO (1) | WO2016073246A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3488386A4 (en) * | 2016-07-22 | 2020-02-19 | Cornell University | Rapid prototyping and in vitro modeling of patient-specific coronary artery bypass grafts |
WO2021091668A1 (en) * | 2019-11-08 | 2021-05-14 | Fresenius Medical Care Holdings,Inc. | Techniques for image-based examination of dialysis access sites |
US20210275391A1 (en) * | 2018-07-20 | 2021-09-09 | Regents Of The University Of Minnesota | Closed-loop system for cardiopulmonary resuscitation (cpr) |
US11446075B2 (en) | 2014-06-04 | 2022-09-20 | Csa Medical, Inc. | Method and system for consistent, repeatable, and safe cryospray treatment of airway tissue |
CN116919374A (en) * | 2023-07-19 | 2023-10-24 | 西安交通大学 | Intracranial aneurysm and method and system for evaluating blood flow dynamics parameters in aneurysm-carrying artery |
US12017413B2 (en) * | 2016-06-10 | 2024-06-25 | Xeltis Ag | System for producing a graft device with a three dimensional covering |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014182505A1 (en) | 2013-05-10 | 2014-11-13 | Stenomics, Inc. | Modeling and simulation system for optimizing prosthetic heart valve treatment |
US9092743B2 (en) | 2013-10-23 | 2015-07-28 | Stenomics, Inc. | Machine learning system for assessing heart valves and surrounding cardiovascular tracts |
US11113812B2 (en) | 2015-08-14 | 2021-09-07 | Elucid Bioimaging Inc. | Quantitative imaging for detecting vulnerable plaque |
US11094058B2 (en) | 2015-08-14 | 2021-08-17 | Elucid Bioimaging Inc. | Systems and method for computer-aided phenotyping (CAP) using radiologic images |
US12008751B2 (en) | 2015-08-14 | 2024-06-11 | Elucid Bioimaging Inc. | Quantitative imaging for detecting histopathologically defined plaque fissure non-invasively |
US10176408B2 (en) | 2015-08-14 | 2019-01-08 | Elucid Bioimaging Inc. | Systems and methods for analyzing pathologies utilizing quantitative imaging |
US11087459B2 (en) | 2015-08-14 | 2021-08-10 | Elucid Bioimaging Inc. | Quantitative imaging for fractional flow reserve (FFR) |
US11071501B2 (en) | 2015-08-14 | 2021-07-27 | Elucid Bioiwaging Inc. | Quantitative imaging for determining time to adverse event (TTE) |
US11676359B2 (en) | 2015-08-14 | 2023-06-13 | Elucid Bioimaging Inc. | Non-invasive quantitative imaging biomarkers of atherosclerotic plaque biology |
US11813104B2 (en) | 2017-10-06 | 2023-11-14 | Emory University | Methods and systems for determining hemodynamic information for one or more arterial segments |
US11871995B2 (en) | 2017-12-18 | 2024-01-16 | Hemolens Diagnostics Sp. Z O.O. | Patient-specific modeling of hemodynamic parameters in coronary arteries |
US11508063B2 (en) | 2019-08-05 | 2022-11-22 | Elucid Bioimaging Inc. | Non-invasive measurement of fibrous cap thickness |
US11772361B2 (en) | 2020-04-02 | 2023-10-03 | Corning Incorporated | Curved glass constructions and methods for forming same |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2349731B (en) * | 1998-01-28 | 2003-06-04 | Ht Medical Systems Inc | Interface device and method for interfacing instruments to vascular access simulation systems |
US8200466B2 (en) * | 2008-07-21 | 2012-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Method for tuning patient-specific cardiovascular simulations |
US8315812B2 (en) | 2010-08-12 | 2012-11-20 | Heartflow, Inc. | Method and system for patient-specific modeling of blood flow |
WO2013017639A1 (en) * | 2011-08-01 | 2013-02-07 | Laminate Medical Technologies Ltd | Vessel shaping devices and methods |
KR20140074904A (en) * | 2011-08-26 | 2014-06-18 | 이비엠 가부시키가이샤 | Bloodstream simulation system for simulating blood vessel treatment effect, method therefor, and computer software program |
US10433740B2 (en) * | 2012-09-12 | 2019-10-08 | Heartflow, Inc. | Systems and methods for estimating ischemia and blood flow characteristics from vessel geometry and physiology |
US10398386B2 (en) | 2012-09-12 | 2019-09-03 | Heartflow, Inc. | Systems and methods for estimating blood flow characteristics from vessel geometry and physiology |
US9042613B2 (en) | 2013-03-01 | 2015-05-26 | Heartflow, Inc. | Method and system for determining treatments by modifying patient-specific geometrical models |
-
2015
- 2015-01-13 US US14/595,503 patent/US9336354B1/en active Active
- 2015-10-28 WO PCT/US2015/057731 patent/WO2016073246A1/en active Application Filing
- 2015-10-28 EP EP15794404.2A patent/EP3215967B1/en active Active
- 2015-10-28 JP JP2017523809A patent/JP6637975B2/en active Active
-
2016
- 2016-02-26 US US15/054,622 patent/US10314654B2/en active Active
-
2019
- 2019-04-29 US US16/397,218 patent/US20190247124A1/en active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11446075B2 (en) | 2014-06-04 | 2022-09-20 | Csa Medical, Inc. | Method and system for consistent, repeatable, and safe cryospray treatment of airway tissue |
US11963709B2 (en) | 2014-06-04 | 2024-04-23 | Csa Medical, Inc. | Method and system for consistent, repeatable, and safe cryospray treatment of airway tissue |
US12017413B2 (en) * | 2016-06-10 | 2024-06-25 | Xeltis Ag | System for producing a graft device with a three dimensional covering |
EP3488386A4 (en) * | 2016-07-22 | 2020-02-19 | Cornell University | Rapid prototyping and in vitro modeling of patient-specific coronary artery bypass grafts |
US10912865B2 (en) | 2016-07-22 | 2021-02-09 | Cornell University | Rapid prototyping and in vitro modeling of patient-specific coronary artery bypass grafts |
US20210275391A1 (en) * | 2018-07-20 | 2021-09-09 | Regents Of The University Of Minnesota | Closed-loop system for cardiopulmonary resuscitation (cpr) |
WO2021091668A1 (en) * | 2019-11-08 | 2021-05-14 | Fresenius Medical Care Holdings,Inc. | Techniques for image-based examination of dialysis access sites |
CN116919374A (en) * | 2023-07-19 | 2023-10-24 | 西安交通大学 | Intracranial aneurysm and method and system for evaluating blood flow dynamics parameters in aneurysm-carrying artery |
Also Published As
Publication number | Publication date |
---|---|
US10314654B2 (en) | 2019-06-11 |
US9336354B1 (en) | 2016-05-10 |
EP3215967A1 (en) | 2017-09-13 |
US20190247124A1 (en) | 2019-08-15 |
EP3215967B1 (en) | 2021-06-02 |
JP2017533041A (en) | 2017-11-09 |
JP6637975B2 (en) | 2020-01-29 |
WO2016073246A1 (en) | 2016-05-12 |
US20160175053A1 (en) | 2016-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10314654B2 (en) | Systems and methods for simulation of hemodialysis access and optimization | |
US11576626B2 (en) | Systems and methods for numerically evaluating vasculature | |
US11918293B2 (en) | Systems and methods for assessing organ and/or tissue transplantation by simulating one or more transplant characteristics | |
AU2017332031B2 (en) | System and methods for estimation of blood flow characteristics using reduced order model and machine learning | |
US10553317B2 (en) | Systems and methods for embolism prediction using embolus source and destination probabilities | |
EP2963574A2 (en) | Method and system for prediction of post-stenting hemodynamic metrics for treatment planning of arterial stenosis | |
de Zélicourt et al. | Patient-specific surgical planning, where do we stand? The example of the Fontan procedure | |
Neidlin et al. | Hemodynamic analysis of outflow grafting positions of a ventricular assist device using closed-loop multiscale CFD simulations: Preliminary results | |
JP2018515167A (en) | System and method for identifying and visualizing functional relationship between vascular network and perfused tissue | |
Sughimoto et al. | Total cavopulmonary connection is superior to atriopulmonary connection Fontan in preventing thrombus formation: computer simulation of flow-related blood coagulation | |
Brown et al. | Importance of realistic LVAD profiles for assisted aortic simulations: evaluation of optimal outflow anastomosis locations | |
US20220044825A1 (en) | Modeling of flow through a left ventricular assist device (lvad) | |
Prather et al. | Computational fluid dynamics study of cerebral thromboembolism risk in ventricular assist device patients: Effects of pulsatility and thrombus origin | |
Itu et al. | Personalized blood flow computations: A hierarchical parameter estimation framework for tuning boundary conditions | |
Huberts | Personalized computational modeling of vascular access creation | |
Kung et al. | Hemodynamics after Fontan procedure are determined by patient characteristics and anastomosis placement not graft selection: a patient-specific multiscale computational study | |
US20210000471A1 (en) | Tailored venous anastomosis for arteriovenous grafts | |
Jorge et al. | Human blood circulatory system modeling based on hybrid systems | |
Bletsos et al. | Hemodynamics in arterial bypass graft anastomoses with varying cuff sizes and proximal flow paths: a fluid–structure interaction study | |
Li et al. | Effects of different bypass surgeries on LSA revascularization in patients with left subclavian occlusion | |
Wongchadakul et al. | Comparative analysis of RADAR vs. conventional techniques for AVF maturation in patients with blood viscosity and vessel elasticity-related diseases through fluid-structure interaction modeling: Anemia, hypertension, and diabetes | |
Goedhals | Modelling Blood Flow During Syringing | |
Chaudhuri | Computer Modelling Informed Coronary Artery Bypass Grafting | |
Ginn-Hedman | Investigation of Ventricular Assist Device Inflow Cannula Configurations within Single Ventricle Hearts | |
Zervides et al. | A simple Computational Model-Based Validation of Guyton's closed circuit analysis of the heart and the peripheral circulatory system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HEARTFLOW, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SANKARAN, SETHURAMAN;GRADY, LEO J.;TAYLOR, CHARLES A.;AND OTHERS;REEL/FRAME:034822/0787 Effective date: 20150105 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |
|
AS | Assignment |
Owner name: HAYFIN SERVICES LLP, UNITED KINGDOM Free format text: SECURITY INTEREST;ASSIGNOR:HEARTFLOW, INC.;REEL/FRAME:055037/0890 Effective date: 20210119 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |
|
AS | Assignment |
Owner name: HAYFIN SERVICES LLP, UNITED KINGDOM Free format text: SECURITY INTEREST;ASSIGNOR:HEARTFLOW, INC.;REEL/FRAME:067775/0966 Effective date: 20240614 |